Phase 3 Data on Brilaroxazine for Schizophrenia with Larry Ereshefsky, PharmD
In an interview with HCPLive, Larry Ereshefsky, PharmD, discussed the phase 3 RECOVER trial assessing brilaroxazine at 50 mg and 15 mg for acute schziophrenia.
In an interview with HCPLive, Larry Ereshefsky, PharmD, discussed the phase 3 RECOVER trial assessing brilaroxazine at 50 mg and 15 mg for acute schziophrenia.
This cross-sectional study evaluates the prevalence of and characteristics associated with discontinuation of cancer treatment among patients who received a diagnosis of COVID-19 during their…
People with higher genetic risk for depression, schizophrenia and bipolar disorder are more likely to have unusual activity levels of “fossil viruses” in their genomes
Johann Hari’s new book about the Ozempic revolution does a good job with the benefits and risks of taking these drugs — the Magic Pills…
During a panel at MedCity News’ INVEST conference, venture capitalists shared some of their takes on today’s healthcare funding landscape — including their thoughts on…
Mum-of-one Hazel Stewart had never played the sport before and took it up after her cancer treatment.
Three pharmaceutical industry executives donated to a a failed Senate candidate, New Jersey’s first lady Tammy Murphy
From the Antisemitism Task Force: How to Repair a Fractured Harvard | Opinion | The Harvard Crimson
An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test.
(Cell Reports 31, 107518.1–16.e1–e5; April 14, 2020)